Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal ...
@article{sequence, author = {Xiaoliang Wu and Alexander Kolar and Joaquin Chung and Dong Jin and Tian Zhong and Rajkumar Kettimuthu and Martin Suchara}, title = {SeQUeNCe: a customizable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback